The funding round was led by Oxford Science Enterprises to support growth in the US and UK markets.
"We invest in companies with the potential to become leaders in their field, and that is why we’re proud to back the incredible team at Navenio on their latest fundraise. Navenio is revolutionising the way we create more efficient healthcare workplaces, through its proven technology powered platform for indoor mapping, and we are excited to continue supporting the team on the next stage of the company’s journey as they look to deliver its offering to a wider range of use cases and across new geographies."
— Heather Roxborough, senior partner of Health Tech
The financing round was co-led by Lansdowne Partners, Oxford Science Enterprises, and Parkwalk Advisors.
"Global agriculture needs a new Green Revolution if we are to feed the world sustainably. Being able to control weeds is critical to both yield and the cost of production in most crops and new herbicide modes of action are essential. It’s very exciting to see moa starting to play its part in this new revolution by advancing so far in such little time."
The Oxford Science Enterprises-led round will support US expansion and continued domestic growth in healthcare.
"I’m delighted our investors have again demonstrated their belief in the vast potential that Navenio can bring by ensuring ‘right person, right place, right time’. Artificial intelligence is one of many technologies making a real-world impact in the health sector, and this investment enables the company to rapidly spearhead international digital transformation."
The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.
"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
